Record Details

Microtubule assembly dynamics: an attractive target for anticancer drugs

DSpace at IIT Bombay

View Archive Info
 
 
Field Value
 
Title Microtubule assembly dynamics: an attractive target for anticancer drugs
 
Creator SINGH, P
RATHINASAMY, K
MOHAN, R
PANDA, D
 
Subject microtubule dynamics
tubulin
cancer drugs
mitosis
benomyl
griseofulvin
sulfonamides
vinblastine
paclitaxel
refractory prostate-cancer
beta-tubulin gene
aspergillus-nidulans
phase-ii
chromosome segregation
estramustine phosphate
cell proliferation
structural basis
mitotic spindle
colchicine site
 
Description Microtubules, composed of alpha beta tubulin dimers, are dynamic polymers of eukaryotic cells. They play important roles in various cellular functions including mitosis. Microtubules exhibit differential dynamic behaviors during different phases of the cell cycle. Inhibition of the microtubule assembly dynamics causes cell cycle arrest leading to apoptosis; thus, qualifying them as important drug targets for treating several diseases including cancer, neuronal, fungal, and parasitic diseases. Although several microtubule-targeted drugs are successfully being used in cancer chemotherapy, the development of resistance against these drugs and their inherent toxicities warrant the development of new agents with improved efficacy. Several antimicrotubule agents are currently being evaluated for their possible uses in cancer chemotherapy. Benomyl, griseofulvin, and sulfonamides have been used as antifungal and antibacterial drugs. Recent reports have shown that these drugs have potent antitumor potential. These agents are shown to inhibit proliferation of different types of tumor cells and induce apoptosis by targeting microtubule assembly dynamics. However, unlike vincas and taxanes, which inhibit cancer cell proliferation in nanomolar concentration range, these agents act in micromolar range and are considered to have limited toxicities. Here, we suggest that these drugs may have a significant use in cancer chemotherapy when used in combination with other anticancer drugs. (C) 2008 IUBMB.
 
Publisher JOHN WILEY & SONS INC
 
Date 2011-10-13T19:05:55Z
2011-12-15T09:16:04Z
2011-10-13T19:05:55Z
2011-12-15T09:16:04Z
2008
 
Type Review
 
Identifier IUBMB LIFE,60(6)368-375
1521-6543
http://dx.doi.org/10.1002/iub.42
http://dspace.library.iitb.ac.in/xmlui/handle/10054/13823
http://hdl.handle.net/100/2979
 
Language en